Growth Metrics

Vertex Pharmaceuticals (VRTX) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $6.3 billion.

  • Vertex Pharmaceuticals' Cash & Current Investments fell 364.01% to $6.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 billion, marking a year-over-year decrease of 364.01%. This contributed to the annual value of $6.1 billion for FY2024, which is 4548.28% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Cash & Current Investments stood at $6.3 billion for Q3 2025, which was down 364.01% from $6.4 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Cash & Current Investments registered a high of $11.9 billion during Q3 2023, and its lowest value of $5.8 billion during Q2 2024.
  • For the 5-year period, Vertex Pharmaceuticals' Cash & Current Investments averaged around $8.3 billion, with its median value being $7.5 billion (2021).
  • Per our database at Business Quant, Vertex Pharmaceuticals' Cash & Current Investments skyrocketed by 6523.35% in 2021 and then plummeted by 4842.16% in 2024.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Cash & Current Investments stood at $7.5 billion in 2021, then skyrocketed by 43.24% to $10.8 billion in 2022, then rose by 4.08% to $11.2 billion in 2023, then plummeted by 45.48% to $6.1 billion in 2024, then increased by 2.8% to $6.3 billion in 2025.
  • Its Cash & Current Investments was $6.3 billion in Q3 2025, compared to $6.4 billion in Q2 2025 and $6.2 billion in Q1 2025.